|
|
TherapeuticsMD Announces Third Quarter 2021 Financial Results
|
|
|
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
|
|
|
TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
|
|
|
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
|
|
|
Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month
|
|
|
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector
|
|
|
TherapeuticsMD Announces Appointment of Hugh O’Dowd as President
|
|
|
TherapeuticsMD Announces Second Quarter 2021 Financial Results
|
|
|
TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
|
|
|
TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA
|
|
|
The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award
|
|
|
TherapeuticsMD Announces First Quarter 2021 Financial Results
|
|
|
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting
|
|
|
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021
|
|
|
TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium
|
|
|
TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results
|
|
|
TherapeuticsMD Announces Participation in Upcoming Investor Conferences
|
|
|
TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021
|
|
|
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
|
|
|
TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock
|
|
|
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
|
